UNSPSC 51332803: Acetophenazine

This classification denotes an antipsychotic agent with the molecular formula C23H29N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8620H6K4QH, chemically known as ketone, 10-(3-(4-(2-hydroxyethyl-1-piperazinyl)propyl)phenothiazin-2-yl methyl but generally known as acetophenazine, which bears US NIH Compound Identifier 17676. Acetophenazine comes in forms base, dimaleate, and maleate. European Medicines Agency schedules Acetophenazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05225MIG.

UNSPSC 51332803 Acetophenazine is a Commodity code that state and local governments tag for pharmaceutical procurement, though recent activity shows the code captures a broader range of health-related pharmaceutical and over-the-counter products rather than acetophenazine specifically. The issuing bodies soliciting under this code include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida and the Texas Health and Human Services Commission represent the primary recent users, alongside the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which aggregates demand across state and local government facilities in multiple states including Minnesota and Oregon. The work involves procurement of finished pharmaceutical products—naloxone, generic multi-source pharmaceuticals, and OTC products—for distribution through authorized wholesalers or direct delivery to county health facilities, with vendors responsible for compliance with Good Manufacturing Practices (cGMP), the Drug Supply Chain Security Act (DSCSA), FDA requirements, and federal environmental regulations when FEMA funds the contract.

Recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county's community health building in Sanford, Florida; the Texas HHS Commission's Request for Information HHS0017013 (posted April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers to participating state and local facilities, with contract term effective July 1, 2026 and price competitiveness weighted at 75 percent of the evaluation. Geographic activity centers on Florida and the upper Midwest and Pacific Northwest through the cooperative purchasing vehicle, with multistate scope through MMCAP's footprint.